<DOC>
	<DOCNO>NCT00423150</DOCNO>
	<brief_summary>This study propose evaluate efficacy safety temozolomide , oral anti-cancer agent , participant population select biomarker . Participants colorectal cancer , non-small-cell lung cancer , head neck cancer , esophageal cancer include .</brief_summary>
	<brief_title>Phase 2 Study Temozolomide Pre-Selected Advanced Aerodigestive Tract Cancers ( Study P04273AM2 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Participants must least 18 year age . Participants must metastatic colorectal cancer ( CRC ) , recurrent metastatic head &amp; neck ( H &amp; N ) esophageal cancer , locally advanced , inoperable , metastatic nonsmall cell lung cancer ( NSCLC ) . Participants must tumor sample blood sample test positive presence biomarker . Participants may 3 prior regimen CRC , 3 prior regimen NSCLC , 2 prior regimen H &amp; N esophageal cancer . Participants must least one measurable lesion . Participants must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Participants must adequate hematologic , renal , liver function . Participants must able take study medication capsule orally , feed tube without capsule open . Participants childbearing potential must agree use medically accept method contraception . Participants receive treatment second malignancy within 1 year screening , consider risk relapse within 1 year screening . Participants unstable progressing central nervous system ( CNS ) metastasis . Participants know CNS metastasis may include ) subject asymptomatic , b ) requirement steroid antiseizure medication , require dos stable , c ) associate midline shift ( opinion investigator ) significant edema . Participants receive prior temozolomide dacarbazine treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>